New Basal Insulin Toujeo Solostar: Increased Therapeutic Potential for the Control of Dysglycaemia in Diabetes Mellitus

Abstract

This review examines the new formulation of insulin glargine (recombinant) in the form of injections 300 U/ml (Gla‑300, Toujeo®). Gla‑300 is a next generation basal insulin with a novel formulation of insulin glargin delivering the same amount of insulin, as Gla‑100 (Lantus®), in 1/3 of the volume. Following the subcutaneous injection, the pharmacokinetic and pharmacodynamic profiles of Gla‑300 are more stable and prolonged (beyond 24 hours) compared with Gla‑100, due to a more gradual and extended release of glargine from the subcutaneous depot (Gla‑300 forms a more compact subcutaneous depot with a smaller surface compared to Gla‑100). The clinical efficacy and safety of Gla‑300 in people with type 1 and type 2 diabetes mellitus are discussed with an emphasis on recently released data from the EDITION (phase 3a) clinical trials. Gla‑300 demonstrates comparable glycaemic control and similar safety profile with lower incidence of hypoglycaemia events (first of all, nocturnal hypoglycemia) compared to Gla‑100. Gla‑300 provided a flexible regimen of insulin administration (24 ± 3 h in the morning vs in the evening) and was associated with less body weight gain.

Keywords

• diabetes mellitus
• glycated hemoglobin
• hypoglycaemia
• insulin
• glargine
• Gla‑100 (Lantus®)
• Gla‑300 (Toujeo®)